Short description
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for the treatment of cancer and other major diseases.
Description
Karyopharm Therapeutics is a biopharmaceutical company with a focus on the development of novel drugs for the treatment of cancer, inflammation, and diseases related to cell proliferation. Karyopharm Therapeutics is developing small molecule drugs that will modulate the activity of critical pathways in cancer, inflammation, and cell proliferation (e.g. FOXO, NFкB, P53, pRB) by targeting the nuclear pore complex machinery, which controls the import and export of proteins between the nucleus and cytoplasm. To successfully control transport through the nuclear pore complex, the company will use its unique technology platform, developed by Sharon Shacham, to identify novel small molecules, optimize them into clinical candidates, and evaluate them in subsequent human clinical studies.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Newton, Massachusetts, United States, North America
Founded on
January 1, 2008
Exited on
November 6, 2013
Went public on
November 6, 2013
Stock symbol
KPTI
Non-profit?
No
Acquired?
No
Employees count
251-500
Revenue range
$7890 - 12340
Sign in for full access
Investors
Noaccess, Blurry Noaccess, No Way, Noaccess, Absolutely Noaccess, Noaccess, No Way, Absolutely Noaccess, Noaccessforu, Noaccess, Noaccess, Noway Youcantaccess, Noaccessforu, Absolutely Noaccess
Sign in for full access
Founders
Michael Christiano, Ronald A. DePinho, Sharon Shacham